Analysis of KRAS mutations in colorectal cancer and their clinical,pathological,and laboratory characteristics
10.3969/j.issn.1673-4130.2024.24.017
- VernacularTitle:结直肠癌KRAS基因突变与临床病理及实验室特征的关系分析
- Author:
Qinwen BA
1
;
Xu YUAN
;
Yun WANG
;
Yanjun LU
Author Information
1. 华中科技大学同济医学院附属同济医院检验科,湖北武汉 430030
- Keywords:
colorectal neoplasms;
KRAS;
mutation;
clinicopathological characteristics
- From:
International Journal of Laboratory Medicine
2024;45(24):3030-3034
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the correlation between KRAS gene mutations and their clinical,path-ological,and laboratory characteristics in patients with colorectal cancer.Methods KRAS gene mutation de-tection was performed using the Mutation Amplification System PCR(ARMS-PCR)method.297 colorectal cancer patients were divided into[KRAS wild-type(KRAS-WT)group and KRAS mutant type(KRAS-MT)group]based on their KRAS gene mutation status.Data on patient gender,age,primary site,metastatic infil-tration,TMN staging,pathological type,differentiation degree,immunohistochemistry,and serum tumor markers were collected.Statistical analysis was performed.Results Among 297 colorectal cancer patients,the total mutation rate of KRAS gene was 47.81％(142/297),with the highest mutation rate at the locus on exon 2,accounting for 35.69％(106/297).Compared with the KRAS-WT group,the KRAS-MT group had a higher proportion of patients with the primary site being the right colon and females(P＜0.05).There was a statis-tically significant difference in the proportion of Ki67 positive cells among the exon 2 mutation group,the exon 3 and 4 mutation group,and the KRAS-WT group(P＜0.05).There were statistically significant differences in serum CEA and CA199 levels among the exon 2 mutation group,exon 3 and 4 mutation groups,and KRAS-WT group(P＜0.05).Conclusion There is a certain correlation between KRAS gene mutation types in colorectal cancer and different clinical,pathological,and laboratory characteristics of patients,which could provide clues for the clinical diagnosis and treatment of colorectal cancer.
